AddLife AB (publ) (ALIF-B.ST)
SEK 137.2
(2.39%)
SEK 137.2
(2.39%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.01 Billion SEK | -14.67% |
| 2022 | 2.61 Billion SEK | 39.78% |
| 2021 | 1.87 Billion SEK | 64.01% |
| 2020 | 1.14 Billion SEK | 14.17% |
| 2019 | 1 Billion SEK | 38.33% |
| 2018 | 723.1 Million SEK | 8.14% |
| 2017 | 668.7 Million SEK | 26.19% |
| 2016 | 529.9 Million SEK | 18.73% |
| 2015 | 446.3 Million SEK | -4.31% |
| 2014 | 466.4 Million SEK | 72.49% |
| 2013 | 270.4 Million SEK | 5.79% |
| 2012 | 255.6 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 781 Million SEK | 0.0% |
| 2024 Q3 | 760 Million SEK | -2.69% |
| 2024 Q1 | 781 Million SEK | -2.74% |
| 2023 Q1 | 668 Million SEK | -6.44% |
| 2023 Q3 | 727 Million SEK | -4.22% |
| 2023 Q2 | 759 Million SEK | 13.62% |
| 2023 FY | 2.23 Billion SEK | -14.67% |
| 2023 Q4 | 803 Million SEK | 10.45% |
| 2022 Q4 | 714 Million SEK | 25.7% |
| 2022 Q2 | 673 Million SEK | 1.51% |
| 2022 Q1 | 663 Million SEK | 21.21% |
| 2022 FY | 2.61 Billion SEK | 39.78% |
| 2022 Q3 | 568 Million SEK | -15.6% |
| 2021 Q4 | 547 Million SEK | 20.75% |
| 2021 FY | 1.87 Billion SEK | 64.01% |
| 2021 Q1 | 332 Million SEK | 2.15% |
| 2021 Q2 | 541 Million SEK | 62.95% |
| 2021 Q3 | 453 Million SEK | -16.27% |
| 2020 FY | 1.14 Billion SEK | 14.17% |
| 2020 Q4 | 325 Million SEK | 24.52% |
| 2020 Q3 | 261 Million SEK | 0.0% |
| 2020 Q2 | 261 Million SEK | -11.53% |
| 2020 Q1 | 295 Million SEK | 11.62% |
| 2019 Q4 | 264.3 Million SEK | 8.32% |
| 2019 Q1 | 243 Million SEK | 27.16% |
| 2019 Q3 | 244 Million SEK | -2.01% |
| 2019 Q2 | 249 Million SEK | 2.47% |
| 2019 FY | 1 Billion SEK | 38.33% |
| 2018 Q2 | 184 Million SEK | 3.95% |
| 2018 FY | 723.1 Million SEK | 8.14% |
| 2018 Q4 | 191.1 Million SEK | 11.75% |
| 2018 Q3 | 171 Million SEK | -7.07% |
| 2018 Q1 | 177 Million SEK | -0.95% |
| 2017 Q2 | 170 Million SEK | 3.03% |
| 2017 FY | 668.7 Million SEK | 26.19% |
| 2017 Q3 | 155 Million SEK | -8.82% |
| 2017 Q1 | 165 Million SEK | 13.71% |
| 2017 Q4 | 178.7 Million SEK | 15.29% |
| 2016 Q2 | 127.4 Million SEK | 42.99% |
| 2016 Q3 | 115.8 Million SEK | -9.11% |
| 2016 Q1 | 89.1 Million SEK | -30.39% |
| 2016 Q4 | 145.1 Million SEK | 25.3% |
| 2016 FY | 529.9 Million SEK | 18.73% |
| 2015 FY | 446.3 Million SEK | -4.31% |
| 2015 Q3 | 107.7 Million SEK | 48.96% |
| 2015 Q4 | 128 Million SEK | 18.85% |
| 2015 Q1 | 254.2 Million SEK | 227.16% |
| 2015 Q2 | 72.3 Million SEK | -71.56% |
| 2014 FY | 466.4 Million SEK | 72.49% |
| 2014 Q4 | 77.7 Million SEK | 0.0% |
| 2013 FY | 270.4 Million SEK | 5.79% |
| 2012 FY | 255.6 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Biotage AB (publ) | 637 Million SEK | -373.155% |
| Bonesupport Holding AB (publ) | 510.93 Million SEK | -489.905% |
| Doxa AB (publ) | -259.5 Million SEK | 1261.464% |
| Elekta AB (publ) | 3.39 Billion SEK | 11.091% |
| iZafe Group AB (publ) | 35.92 Million SEK | -8289.0% |
| Ortivus AB (publ) | 48.45 Million SEK | -6120.461% |
| Ortivus AB (publ) | 48.45 Million SEK | -6120.461% |
| Q-linea AB (publ) | -43 Thousand SEK | 7009402.326% |
| S2Medical AB (publ) | 20.3 Million SEK | -14746.657% |
| Synsam AB (publ) | 3.76 Billion SEK | 19.883% |